The UK Standardisation of Breast Radiotherapy (START) Trial B of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: a Randomised Trial

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2008 Mar 22

PMID 18355913

Citations 329

Authors

R K Agrawal

E G A Aird

J M Barrett

P J Barrett-Lee

S M Bentzen

J M Bliss

J Brown

J A Dewar

H J Dobbs

J S Haviland

P J Hoskin

P Hopwood

P A Lawton

B J Magee

J Mills

D A L Morgan

J R Owen

S Simmons

G Sumo

M A Sydenham

K Venables

J R Yarnold

Affiliations

Soon will be listed here.

Abstract

Background: The international standard radiotherapy schedule for early breast cancer delivers 50 Gy in 25 fractions of 2.0 Gy over 5 weeks, but there is a long history of non-standard regimens delivering a lower total dose using fewer, larger fractions (hypofractionation). We aimed to test the benefits of radiotherapy schedules using fraction sizes larger than 2.0 Gy in terms of local-regional tumour control, normal tissue responses, quality of life, and economic consequences in women prescribed post-operative radiotherapy.

Methods: Between 1999 and 2001, 2215 women with early breast cancer (pT1-3a pN0-1 M0) at 23 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2.0 Gy over 5 weeks or 40 Gy in 15 fractions of 2.67 Gy over 3 weeks. Women were eligible for the trial if they were aged over 18 years, did not have an immediate reconstruction, and were available for follow-up. Randomisation method was computer generated and was not blinded. The protocol-specified principal endpoints were local-regional tumour relapse, defined as reappearance of cancer at irradiated sites, late normal tissue effects, and quality of life. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779.

Findings: 1105 women were assigned to the 50 Gy group and 1110 to the 40 Gy group. After a median follow up of 6.0 years (IQR 5.0-6.2) the rate of local-regional tumour relapse at 5 years was 2.2% (95% CI 1.3-3.1) in the 40 Gy group and 3.3% (95% CI 2.2 to 4.5) in the 50 Gy group, representing an absolute difference of -0.7% (95% CI -1.7% to 0.9%)--ie, the absolute difference in local-regional relapse could be up to 1.7% better and at most 1% worse after 40 Gy than after 50 Gy. Photographic and patient self-assessments indicated lower rates of late adverse effects after 40 Gy than after 50 Gy.

Interpretation: A radiation schedule delivering 40 Gy in 15 fractions seems to offer rates of local-regional tumour relapse and late adverse effects at least as favourable as the standard schedule of 50 Gy in 25 fractions.

Citing Articles

Sequential or simultaneous-integrated boost in early-stage breast cancer patients: trade-offs between skin toxicity and risk of compromised coverage.

Zhong C, Huang M, Yu H, Yuan J, Xie R, Lai Z Radiat Oncol. 2025; 20(1):10.

PMID: 39833842 PMC: 11744842. DOI: 10.1186/s13014-025-02584-0.

Therapeutic Management in Elderly Male Breast Cancer Patients: A Scoping Review.

Di Rito A, Grillo A, Carbonara R Curr Oncol Rep. 2025; 27(2):120-134.

PMID: 39826033 DOI: 10.1007/s11912-024-01629-z.

Size Matters: Predicting Surgical Site Infection After Whole Breast Radiotherapy in the Era of Hypofractionation.

Lee S, Kim Y, Song J, Yu M, Rhu J, Paik P J Clin Med. 2025; 14(1.

PMID: 39797265 PMC: 11720973. DOI: 10.3390/jcm14010184.

Guiding Sole Intraoperative Radiotherapy in Breast Cancer According to ASTRO Guidelines: Mitigating Adverse Outcomes in a Taiwan Single-Center.

Yang H, Tsang Y, Tu C, Hsu Y Cancer Med. 2024; 14(1):e70537.

PMID: 39739750 PMC: 11683544. DOI: 10.1002/cam4.70537.

Navigating through recent evidence on locoregional breast cancer radiotherapy: an initiative by the scientific association of Swiss radiation oncology.

Tsoutsou P, Eberhardt A, Gruber G, Henke G, Jeannerret-Sozzi W, Linsenmeier C Strahlenther Onkol. 2024; 201(2):93-105.

PMID: 39643658 PMC: 11754371. DOI: 10.1007/s00066-024-02332-5.

References

Yamada Y, Ackerman I, Franssen E, MacKenzie R, Thomas G . Does the dose fractionation schedule influence local control of adjuvant radiotherapy for early stage breast cancer?. Int J Radiat Oncol Biol Phys. 1999; 44(1):99-104. DOI: 10.1016/s0360-3016(98)00507-0. View

Ash D, Benson E, Sainsbury J, Round C, Head C . Seven-year follow-up on 334 patients treated by breast conserving surgery and short course radical postoperative radiotherapy: a report of the Yorkshire Breast Cancer Group. Clin Oncol (R Coll Radiol). 1995; 7(2):93-6. DOI: 10.1016/s0936-6555(05)80808-8. View

Altman D, Andersen P . Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999; 319(7223):1492-5. PMC: 1117211. DOI: 10.1136/bmj.319.7223.1492. View

Fisher B, Costantino J, Redmond C, Fisher E, MARGOLESE R, Dimitrov N . Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993; 328(22):1581-6. DOI: 10.1056/NEJM199306033282201. View

Venables K, Miles E, Aird E, Hoskin P . What is the optimum breast plan: a study based on the START trial plans. Br J Radiol. 2006; 79(945):734-9. DOI: 10.1259/bjr/80814021. View

Peters M . Carcinoma of the breast. Stage II--radiation range. Wedge resection and irradiation. An effective treatment in early breast cancer. JAMA. 1967; 200(2):134-5. DOI: 10.1001/jama.200.2.134. View

Venables K, Winfield E, Deighton A, Aird E, Hoskin P . Breast radiotherapy phantom design for the START trial. START trial management group. Br J Radiol. 2001; 73(876):1313-6. DOI: 10.1259/bjr.73.876.11205676. View

Venables K, Winfield E, Deighton A, Aird E, Hoskin P . A survey of radiotherapy quality control practice in the United Kingdom for the START trial. Radiother Oncol. 2001; 60(3):311-8. DOI: 10.1016/s0167-8140(01)00376-0. View

Dische S, JOSLIN C, Miller S . The RAGE litigation. Radiation Action Group Exposure. Lancet. 1998; 351(9120):1967-8. DOI: 10.1016/s0140-6736(05)78663-3. View

10.

van Dongen J, Bartelink H, Fentiman I, Lerut T, Mignolet F, Olthuis G . Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr. 1992; (11):15-8. View

11.

Venables K, Miles E, Aird E, Hoskin P . The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial. Radiother Oncol. 2004; 71(3):303-10. DOI: 10.1016/j.radonc.2004.02.008. View

12.

Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M . Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993; 328(22):1587-91. DOI: 10.1056/NEJM199306033282202. View

13.

Olivotto I, Weir L, Kim-Sing C, Bajdik C, Trevisan C, Doll C . Late cosmetic results of short fractionation for breast conservation. Radiother Oncol. 1996; 41(1):7-13. DOI: 10.1016/s0167-8140(96)91824-1. View

14.

Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J . Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005; 75(1):9-17. DOI: 10.1016/j.radonc.2005.01.005. View

15.

Owen J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J . Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006; 7(6):467-71. DOI: 10.1016/S1470-2045(06)70699-4. View

16.

Hopwood P, Fletcher I, Lee A, Al Ghazal S . A body image scale for use with cancer patients. Eur J Cancer. 2001; 37(2):189-97. DOI: 10.1016/s0959-8049(00)00353-1. View

17.

Overgaard M, Bentzen S, Christensen J, Madsen E . The value of the NSD formula in equation of acute and late radiation complications in normal tissue following 2 and 5 fractions per week in breast cancer patients treated with postmastectomy irradiation. Radiother Oncol. 1987; 9(1):1-11. DOI: 10.1016/s0167-8140(87)80213-x. View

18.

Magee B, Stewart A, Swindell R . Outcome of radiotherapy after breast conserving surgery in screen detected breast cancers. Clin Oncol (R Coll Radiol). 1999; 11(1):40-5. DOI: 10.1053/clon.1999.9007. View

19.

Fyles A, McCready D, Manchul L, Trudeau M, Merante P, Pintilie M . Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004; 351(10):963-70. DOI: 10.1056/NEJMoa040595. View

20.

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View